We are launching our official pregnancy and lung cancer registry! DM or send us an email with any cases-data protected and safe. Email: [email protected]

A conclusão é de revisão sistemática publicada no The Breast, em artigo que tem o oncologista Felippe Lazar Neto, do ICESP, como primeiro autor. Leia mais: tinyurl.com/4dr6hs58 #onconews #cancer #novidades

Among PDL1 high NSCLC, PFS and OS better with PDL1 ≥90% compared to 50-89%, report JTO & JTO CRR. Seen with 1L pembrolizumab (PFS HR 0.69, OS HR 0.70) and cemiplimab in EMPOWER-Lung 1 (PFS HR 0.53, OS HR 0.63). PDL1 50-80% enriched for STK11 and SMARCA4 mt jtocrr.org/article/S2666-…

Our work in global representativeness, pharm. funding and cost-effectiveness research have recently been published at The Breast (tinyurl.com/breast-lazarne…). Although our findings are not necessarily new, diving deep in this topic is worthy of some important considerations. /n

Congrats to Instituto do Câncer fellows for achieving for the 3rd year in a row ASCO-ITE highest score! Proud of you all! ASCO 🇧🇷

Mais uma conquista! 🏆 Pelo terceiro ano consecutivo, residentes do segundo e terceiro ano do Programa de Residência Médica em Oncologia Clínica do Icesp obtiveram a média mais alta no exame mundial da Sociedade Americana de Oncologia Clínica (ASCO)!

Taking advantage of the ASCO conference: in your routine, when a cancer patient is hospitalized due to worsening symptoms (e.g., shortness of breath, pain) and the reason for the worsening symptoms is disease progression, how do you record the diagnosis in the medical chart?

We are asking this because it is related to a work we have been doing and will share soon! Lucas Tadeu Stangler,Victor J Yamamoto, Gustavo Benfatti Olivato, @mateusmarinho06,João Wilson, Mateus Z Claro, Cassio Murilo T. Hidalgo Filho, Renata Colombo Bonadio, MD

Os oncologistas Cassio Murilo Hidalgo Filho e Felippe Lazar Neto assinam como primeiro autor. Leia: tinyurl.com/5a5527r5

A nice work by my good friend and fantastic oncologist Felippe Lazar facilitating clinical trial data access to oncologists in Brazil!

Participating in this outstading projeto to uso IA tools to predict IO response in NSCLC!

“A quimioterapia de indução é fundamental para o tratamento do carcinoma nasofaríngeo localmente avançado, mas dados reais sobre sua eficácia e toxicidade são limitados”, observam os pesquisadores. Leia mais: tinyurl.com/4dhxur84 Cassio Murilo T. Hidalgo Filho Instituto do Câncer Sírio-Libanês

🔥 A brilliant case by Cassio Murilo T. Hidalgo Filho in EGFR+ NSCLC ignites one of the hottest debates: MARIPOSA vs FLAURA2 vs FLAURA at #Yin&Yang 2025 conference in Milan 💥 On stage 2 titans Benjamin Besse & Julia Rotow MD face off in a thought-provoking showdown Mihaela Aldea Biagio Ricciuti, MD, PhD

🌓Yin&Yang Masterclass 2025 1st edition comes to an end. Huge thanks to all young and early-career investigators for stepping up, and to the stellar faculty for guiding them with passion and vision. Next stop: Paris 2026 🇨🇵 Stay tuned! #YinYang2025 Mihaela Aldea Biagio Ricciuti, MD, PhD

Honored to be part of the Yin&Yang Lung Cancer Masterclass in Milan 🇮🇹 Presented a case on EGFR-mutant NSCLC, had the chance to see a great debate led by Julia Rotow MD and Benjamin Besse and connected with young oncologists from around the world.